Mereo Biopharma 1 Limited
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
0
Ending by 2030
Mar 2036
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 18, 2027The maintenance fee for Use of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide in the treatment of acute exacerbations of chronic obstructive pulmonary disease (US 11,701,341) comes due Jan 18, 2027. Unpaid by Jul 19, 2027, it lapses early.
- 1 fee due Sep 30, 2027The maintenance fee for Dosage Regimen for the Treatment of Acute Exacerbations of Chronic Obstructive Pulmonary Disease (US 10,603,306) comes due Sep 30, 2027. Unpaid by Mar 31, 2028, it lapses early.
- 1 fee due Oct 14, 2027The maintenance fee for Dosage Regimen for the Treatment of Acute Exacerbations of Inflammatory Conditions (US 10,617,674) comes due Oct 14, 2027. Unpaid by Apr 14, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 9 of 9
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,603,306 | Dosage Regimen for the Treatment of Acute Exacerbations of Chronic Obstructive Pulmonary Disease In force · High confidence | In force | High confidence | |
| US 10,617,674 | Dosage Regimen for the Treatment of Acute Exacerbations of Inflammatory Conditions In force · High confidence | In force | High confidence | |
| US 11,129,810 | Dosage Regimen for the Treatment of Acute Exacerbations of Chronic Obstructive Pulmonary Disease In force · High confidence | In force | High confidence | |
| US 11,434,204 | Method for Producing a Polymorphic Form of 3-[5-Amino-4-(3-Cyanobenzoyl)-PYRAZOL-1-YL]-N-CYCLOPROPYL-4-Methylbenzamide In force · Medium confidence | In force | Medium confidence | |
| US 10,934,260 | Method for Producing a Polymorphic Form of 3-[5-Amino-4-(3- CYANOBENZOYL)-PYRAZOL-1-YL]-N-CYCLOPROPYL-4-Methylbenzamide In force · Medium confidence | In force | Medium confidence | |
| US 10,995,071 | Method for Producing a Polymorphic Form of 3-[5-Amino-4-(3-Cyanobenzoyl)-PYRAZOL-1-YL]-N-CYCLOPROPYL-4-Methylbenzamide In force · High confidence | In force | High confidence | |
| US 11,234,967 | Use of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide in the prevention or reduction of acute exacerbations of chronic obstructive pulmonary disease In force · USPTO record | In force | USPTO record | |
| US 11,701,341 | Use of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide in the treatment of acute exacerbations of chronic obstructive pulmonary disease In force · USPTO record | In force | USPTO record | |
| US 11,649,213 | Synthetic Method for the Preparation of a 3-[5-Amino-4-(3-Cyanobenzoyl)- Pyrazol Compound In force · High confidence | In force | High confidence |
Also on record, not counted in the 9: 1 patent in force now held by others · 4 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
3 abandoned